 A second STEMI manuscript described the study design and demographics of the STRATEGY trial which evaluated STEMI patients who were randomized to receive either SHDB tirofiban sirolimus eluting stent or abciximab bare metal stent. This study confirmed the findings of Danzi and co-workers, and also found that the SHBD tirofiban resulted in the same results, as compared to patients treated with Abciximab, with a trend towards a lower bleeding rate with the SHBD tirofiban regimen8 The ADVANCE trial evaluated the efficacy and safety of SHDB tirofiban compared with placebo in treating high-risk patients9. The study enrolled 202 patients with either a single coronary artery occlusiondiabetes, diagnosed NSTEMI, or multivessel coronary artery disease. This trial demonstrated a statistically significant decrease in 6-month MACE or bailout GP IIbIIIa inhibitor use for patients treated with HDB tirofiban versus placebo 19.8 vs, 34.7; P0.01. SHDB tirofiban was shown to significantly reduce the increase in cardiac markers both troponin I and CK-MB associated with ischemic events. Subgroup analysis showed a statistically significant decrease in lowering the primary endpoint for diabetic and ACS patients treated with SHDB tirofiban. Finally, there was no major bleeding, need for red blood cell transfusion, or severe thrombocytopenia, and there was no significant difference in even minor bleeding rates between SHDB tirofiban-treated patients and those treated with placebo 4 vs. 1; P 0.19. 